| FRIDAY, FEBRUARY 05, 2010 |
| 5:07 AM | Tecan and Enigma Diagnostics enter into manufacturing and supply agreement for Enigma's ML instruments - M2 |
 |
| THURSDAY, FEBRUARY 04, 2010 |
| 7:43 PM | Biota Announces Relenza Royalty for December 2009 Quarter - BusinessWire |
|
| 12:39 PM | XenoPort Announces Horizant(TM) as Brand Name for XP13512 - BusinessWire |
|
| 8:17 AM | GSK - Pharma Boss Aims For 14% Returns On Late Stage Pipeline - PR Newswire |
|
| WEDNESDAY, FEBRUARY 03, 2010 |
| 10:37 AM | America's Pharmaceutical Research Companies Donate $35 Million to Relief Efforts in Haiti; More Help Coming - PR Newswire |
|
| TUESDAY, FEBRUARY 02, 2010 |
| 8:00 AM | Spiriva Will Remain Decision Resources' Clinical Gold Standard Through 2018 for the Treatment of Chronic Obstructive Pulmonary Disease - PR Newswire |
|
| MONDAY, FEBRUARY 01, 2010 |
| 2:58 PM | GSK 2009 Financial Results Announcement and Teleconference Details - PR Newswire |
|
| 9:26 AM | For The Second-Line Treatment of HER2-Positive Metastatic Breast Cancer, A Targeted Treatment That Increases Progression-Free Survival Relative to Tykerb/Tyverb and Xeloda Would Earn Similar Patient Share in the U.S. and Europe - PR Newswire |
|
| 5:36 AM | GlaxoSmithKline announces accelerated approval for TYKERB for metastatic breast cancer - M2 |
|
| FRIDAY, JANUARY 29, 2010 |
| 7:46 PM | GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer - PR Newswire |
|
